bluebird bio Inc (BLUE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
97
About the Report
About the Report
Summary
Bluebird Bio Inc (bluebird bio) is a clinical stage biotechnology company that focuses on the development of new gene therapies for the treatment of severe genetic diseases and cancer. The company develops its products based on integrated product platforms such as gene therapy, cancer immunotherapy and gene editing. Its product pipeline includes Lenti D for the treatment of cerebral adrenoleukodystrophy (CALD); LentiGlobin for the treatment of transfusion-dependent beta thalassemia and sickle cell disease, besides compounds under development for the treatment of various cancers. The company has collaboration with various pharmaceutical companies to discover, develop and commercialize gene therapy products to treat cancer. bluebird bio is headquartered in Cambridge, Massachusetts, the US.
bluebird bio Inc (BLUE)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
bluebird bio Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
bluebird bio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
bluebird bio Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
bluebird bio Raises USD 60 Million In Series D Financing 12
Partnerships 14
bluebird bio and Gritstone Oncology Enter into Agreement 14
Regeneron Pharma and bluebird bio to Enter into Collaboration Agreement 15
Celgene and Bluebird Enter into Co-Development Agreement 16
Kite Pharma Enters into Co-Development Agreement with Bluebird bio 17
bluebird bio Amends Co-Development Agreement With Celgene 18
Licensing Agreements 19
bluebird bio Enters into Licensing Agreement with TC BioPharm 19
GlaxoSmithKline Intellectual Property Development Enters into Licensing Agreement with bluebird bio 20
Novartis Pharma Enters into Licensing Agreement with bluebird bio 21
MediGene Expands Licensing Agreement with bluebird bio 22
Bluebird bio Enters Into Licensing Agreement With ViroMed 23
bluebird bio Enters into Licensing Agreement with National Institutes of Health 24
bluebird bio Enters into Licensing Agreement with Biogen 25
Celgene Exercises its Option to Exclusively License bb21217 with bluebird bio 26
Equity Offering 27
bluebird bio Raises USD632.5 Million in Public Offering of Shares 27
bluebird bio Raises USD651.3 Million in Public Offering of Shares 29
bluebird bio Raises USD460 Million in Public Offering of Shares 31
bluebird bio Raises USD250 Million in Public Offering of Shares 33
Bluebird bio Raises USD500 Million in Public Offering of Shares 35
Bluebird bio Raises USD259 Million in Public Offering of Shares 37
Bluebird bio Raises USD117.3 Million in Public Offering of Shares 39
bluebird bio Completes IPO For USD 116 Million 41
Acquisition 43
Bluebird bio Acquires Precision Genome Engineering 43
bluebird bio Inc-Key Competitors 44
bluebird bio Inc-Key Employees 45
bluebird bio Inc-Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Recent Developments 47
Financial Announcements 47
Nov 01, 2018: bluebird bio reports third quarter 2018 financial results and highlights operational progress 47
Aug 02, 2018: bluebird bio reports second quarter 2018 financial results and highlights operational progress 50
May 02, 2018: bluebird bio Announces First Quarter 2018 Financial Results 53
Feb 21, 2018: bluebird bio Announces Fourth Quarter and Full Year 2017 Financial Results 54
Nov 01, 2017: bluebird bio Reports Third Quarter 2017 Financial Results and Recent Operational Progress 56
Aug 02, 2017: bluebird bio Reports Second Quarter 2017 Financial Results and Recent Operational Progress 58
May 03, 2017: bluebird bio Reports First Quarter 2017 Financial Results and Recent Operational Progress 60
Feb 22, 2017: bluebird bio Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Operational Progress 61
Corporate Communications 63
Feb 14, 2018: bluebird bio Names Alison Finger As Chief Commercial Officer 63
Sep 20, 2017: bluebird bio Appoints Mary Lynne Hedley, Ph.D. to Board of Directors 64
Jun 08, 2017: bluebird bio Appoints John O. Agwunobi, M.D. and Douglas A. Melton, Ph.D. to Board of Directors 65
Product News 66
12/11/2017: bluebird bio Presents Updated Data from HGB-205 Study of LentiGlobin Gene Therapy in Patients with Severe Sickle Cell Disease and Transfusion-Dependent ß-Thalassemia at American Society of Hematology Annual Meeting 66
10/04/2017: bluebird bio Announces Publication of Interim Data from Starbeam Study of Lenti-DTM Drug Product in Patients with Cerebral Adrenoleukodystrophy (CALD) in The New England Journal of Medicine 68
10/04/2017: Gene therapy halts progression of childhood cerebral adrenoleukodystrophy in clinical trial 70
09/06/2017: bluebird bio to Present Interim Clinical Data from Starbeam Study of Lenti-DTM Drug Product in Cerebral Adrenoleukodystrophy at Child Neurology Society 2017 Annual Meeting 72
06/26/2017: bluebird bio Announces Topline Interim Clinical Data from Starbeam Study of Lenti-D Drug Product in Cerebral Adrenoleukodystrophy 73
06/23/2017: bluebird bio Presents New Data from HGB-205 Study of LentiGlobin Drug Product in Patients with Transfusion-Dependent ß-Thalassemia and Severe Sickle Cell Disease at European Hematology Association Annual Meeting 74
06/15/2018: bluebird bio Presents New Data from Northstar (HGB-204) and Northstar-2 (HGB-207) Studies of LentiGlobin Gene Therapy in Patients with Transfusion-Dependent ß-Thalassemia at Annual Congress of the European Hematology Association 76
04/18/2018: bluebird bio Announces New England Journal of Medicine Publication of Interim Data from Two Phase 1/2 Clinical Studies of LentiGlobin Gene Therapy in Patients with Transfusion-Dependent ß-Thalassemia 78
03/01/2017: bluebird bio Announces Publication of Case Study on First Patient with Severe Sickle Cell Disease Treated with Gene Therapy in The New England Journal of Medicine 80
01/31/2018: Sickle cell gene therapy to boost fetal hemoglobin: A 70-year timeline of discovery 81
Clinical Trials 82
Jun 15, 2018: bluebird bio Announces New Interim Data from Phase 1 (HGB-206) Study of LentiGlobin Gene Therapy in Patients with Severe Sickle Cell Disease at Annual Congress of the European Hematology Association 82
May 17, 2018: bluebird bio to Present New Data from LentiGlobin Transfusion-Dependent ß-Thalassemia and Severe Sickle Cell Disease Clinical Studies at Annual Congress of the European Hematology Association 84
Dec 10, 2017: bluebird bio Presents New Data from Clinical Studies of LentiGlobin Gene Therapy in Transfusion-Dependent ß-Thalassemia at American Society of Hematology Annual Meeting 86
Nov 16, 2017: bluebird bio Announces First Patient Treated in Northstar-3 (HGB-212), Phase 3 Study of LentiGlobin in Patients with Transfusion-Dependent ß-Thalassemia (TDT) and ß0/ß0 Genotype 88
Nov 01, 2017: bluebird bio to Present New Data from Clinical Studies of LentiGlobin Gene Therapy in Transfusion-Dependent ß-Thalassemia at ASH Annual Meeting 89
Sep 28, 2017: bluebird bio Announces First Patient Treated with Second Anti-BCMA CAR T bb21217 in CRB-402 Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma 92
Jun 23, 2017: bluebird bio Announces Early Data from Phase 3 Northstar-2 (HGB-207) Study of LentiGlobin Drug Product at European Hematology Association (EHA) Annual Meeting 93
May 18, 2017: bluebird bio to Present New Data from LentiGlobin Clinical Studies at European Hematology Association Annual Meeting 94
Feb 03, 2017: bluebird bio Announces First Patient Treated with LentiGlobin Drug Product Under Amended Study Protocol in HGB-206 Phase 1 Study of Patients with Severe Sickle Cell Disease 95
Other Significant Developments 96
Feb 14, 2018: The Alliance for Regenerative Medicine Announces Initial Slate of Presenting Companies at the Sixth Annual Cell & Gene Therapy Investor Day 96
Appendix 97
Methodology 97
About GlobalData 97
Contact Us 97
Disclaimer 97
List of Figure
List of Figures
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
List of Table
List of Tables
bluebird bio Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
bluebird bio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
bluebird bio Inc, Deals By Therapy Area, 2012 to YTD 2018 9
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
bluebird bio Raises USD 60 Million In Series D Financing 12
bluebird bio and Gritstone Oncology Enter into Agreement 14
Regeneron Pharma and bluebird bio to Enter into Collaboration Agreement 15
Celgene and Bluebird Enter into Co-Development Agreement 16
Kite Pharma Enters into Co-Development Agreement with Bluebird bio 17
bluebird bio Amends Co-Development Agreement With Celgene 18
bluebird bio Enters into Licensing Agreement with TC BioPharm 19
GlaxoSmithKline Intellectual Property Development Enters into Licensing Agreement with bluebird bio 20
Novartis Pharma Enters into Licensing Agreement with bluebird bio 21
MediGene Expands Licensing Agreement with bluebird bio 22
Bluebird bio Enters Into Licensing Agreement With ViroMed 23
bluebird bio Enters into Licensing Agreement with National Institutes of Health 24
bluebird bio Enters into Licensing Agreement with Biogen 25
Celgene Exercises its Option to Exclusively License bb21217 with bluebird bio 26
bluebird bio Raises USD632.5 Million in Public Offering of Shares 27
bluebird bio Raises USD651.3 Million in Public Offering of Shares 29
bluebird bio Raises USD460 Million in Public Offering of Shares 31
bluebird bio Raises USD250 Million in Public Offering of Shares 33
Bluebird bio Raises USD500 Million in Public Offering of Shares 35
Bluebird bio Raises USD259 Million in Public Offering of Shares 37
Bluebird bio Raises USD117.3 Million in Public Offering of Shares 39
bluebird bio Completes IPO For USD 116 Million 41
Bluebird bio Acquires Precision Genome Engineering 43
bluebird bio Inc, Key Competitors 44
bluebird bio Inc, Key Employees 45
bluebird bio Inc, Other Locations 46
bluebird bio Inc, Subsidiaries 46
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.